RNAZ Stock Risk & Deep Value Analysis

TransCode Therapeutics, Inc.

Healthcare • Biotechnology

DVR Score

2.5

out of 10

Risk Trap

The Bottom Line on RNAZ

We analyzed TransCode Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran RNAZ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Oct 9, 2025•Run Fresh Analysis →

📈RNAZ Performance Overview3yr weekly

📊

Unlock RNAZ Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

About TransCode Therapeutics, Inc. (RNAZ)

Sector

Healthcare

Industry

Biotechnology

Market Cap Category

small

Market Cap

$12.34M

RNAZ Deep Value Analysis

TransCode Therapeutics operates in the high-potential RNA oncology market with a proprietary platform. However, severe financial instability, including a critically short cash runway and persistent, heavy share dilution, profoundly undermines any realistic path to 10x per-share growth within 3-5 years. While scientific milestones (IND, Phase 0/1 trials) are noted, the company's financing strategy consistently erodes shareholder value. An unproven competitive advantage and the highly competitive landscape further temper potential. This presents as a significant 'dud' risk for multi-bagger returns due to unsustainable financial trajectory and excessive dilution.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

RNAZ Financial Health Metrics

Market Cap

$12.34M

🔔

Never miss a move on RNAZ

Create a free account to set price alerts and get notified on Telegram when RNAZ hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for TransCode Therapeutics, Inc. (RNAZ)?

As of October 9, 2025, TransCode Therapeutics, Inc. has a DVR Score of 2.5 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of TransCode Therapeutics, Inc.?

TransCode Therapeutics, Inc.'s market capitalization is approximately $12.3M. The company operates in the Healthcare sector within the Biotechnology industry.

What ticker symbol does TransCode Therapeutics, Inc. use?

RNAZ is the ticker symbol for TransCode Therapeutics, Inc.. The company trades on the NCM.

How often is the RNAZ DVR analysis updated?

Our AI-powered analysis of TransCode Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on October 9, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.